• Montreal Doctors Spearhead Cannabis Clinical Trial

    23 January 2017
    0 Views

    Gilles Richard doesn’t harbour any illusions about his disease.

    It has latched itself to his lungs, his bones and he fears it will eventually seep its way into his brain. Over time, he says, the sickness will prevail.

    “I like to say I just want five good years,” says Richard, a retired physicist. “But it could be three, it could be two. … I won’t take anything for granted.”

    Faced with this grim fate, Richard seems unfazed as he sits in the waiting room of the Santé Cannabis medical clinic on Amherst St. in Montreal’s Centre-Sud borough. The 60-year-old wears a suit and tie, he smiles at passersby and offers to chat about topics ranging from molecular biology to the latest episode of The Walking Dead.

    Continue Reading
  • Tetra BioPharma Announces it Has Entered into a Clinical Research Partnership with Santé Cannabis, Québec’s Leading Medical Cannabis Institution

    23 January 2017
    0 Views

    Ottawa, Ontario – (Marketwired – January 23, 2017) – PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP”) (CSE:TBP) is pleased to announce that it has entered into a clinical research partnership with Santé Cannabis. Under the partnership, Santé Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial evidence of the safety and efficacy of PPP001 required for a new prescription drug approval from Health Canada and the USA Food and Drug Administration (“FDA”). These ground-breaking trials seek to receive the first approval for a Canadian-manufactured cannabis-based prescription medication.

    Continue Reading
  • Exclusive Interview with Tetra Bio-Pharma CSO Discussing Task Force Recommendations, DEA — CFN Media

    17 January 2017
    0 Views

    SEATTLE, WA–(Marketwired – Jan 17, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and story covering the effect recent Canadian Cannabis Task Force recommendations and DEA actions could have on Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CSE: TBP) as the company continues development of smokable marijuana as treatment for a variety of conditions.

    Continue Reading
  • Tetra Bio-Pharma Inc. annonce une nouvelle nomination à son conseil consultatif scientifique et clinique

    11 January 2017
    0 Views

    Ottawa (Ontario) – (Marketwired – le 11 janvier 2017) – PhytoPain Pharma Inc. (« PhytoPain Pharma » ou « PPP »), une filiale de Tetra Bio-Pharma Inc. (« Tetra » ou la « Société ») (CSE : TBP), a le plaisir d’annoncer la nomination du Dr Gilles Chamberland, M. D., FRCPC, à son conseil consultatif scientifique et clinique. Le conseil est formé d’experts en recherche clinique, en gestion de la douleur et en conception de médicaments contre le cancer et les affections neurologiques. La nomination du Dr Gilles Chamberland, M. D., au conseil consultatif de PPP conférera à cette dernière l’orientation critique nécessaire à son programme de développement clinique en ce qui concerne l’innocuité des médicaments à base de cannabis et les risques éventuels pour la santé mentale qui sont associés à la consommation de marijuana.

    Continue Reading
  • Tetra Bio-Pharma Inc. Announces A New Appointment to its Scientific and Clinical Advisory Board

    11 January 2017
    0 Views

    Ottawa, Ontario – (Marketwired – January 11, 2017) – PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP), is pleased to announce the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development. The nomination of Dr. Chamberland, M.D., to its Advisory Board will provide critical guidance on PPP’s clinical development program with regards to the safety of cannabis drug products and the potential mental health risks associated with the consumption of marijuana.

    Continue Reading
  • Tetra Bio-Pharma Inc. Enters into Binding Letter of Intent for Co-Development and Commercialization of Health Care Products Containing Cannabinoids and Closes a Private Placement

    10 January 2017
    0 Views

    Ottawa, Ontario – (Marketwired – January 10, 2017) – Tetra Bio-Pharma Inc. (“TetraBio”, “TBP”, or the “Company”) (CSE:TBP and OTC:GROPF) through its subsidiary, Agro-Tek Health Inc. (“GTK”), is pleased to announce that it has entered into a binding letter of intent to form a joint venture with Ford’s Family Pharmacy and Wellness Center (“FFP”) in Moncton, New Brunswick. The primary objective of this venture is the development and commercialization of cannabinoid-based products for the Canadian health care market with a special focus on CBD and THC-free cannabis products for the USA cosmetic and supplement market.

    Continue Reading
  • Tetra Bio-Pharma Looks to Make Cannabis Affordable

    6 December 2016
    0 Views

    Medical cannabis may be legal throughout Canada and nearly 30 U.S. states, but patients cannot always easily access the drug. The lack of clinical trials has left many physicians unwilling to prescribe the medicine, while insurance companies provide little to no coverage. Patients must pay hundreds of dollars per month out-of-pocket for access to the drug, which can be a prohibitive amount for many families – including those with the greatest need.

    In this article, we will take a closer look at how Tetra Bio-Pharma Inc. (OTC: GRPOF) (CSE: TBP) could change these dynamics and make medical cannabis more affordable to everyone.

    Continue Reading
  • Aphria Makes $1,000,000 Investment in Tetra Bio-Pharma Via Private Placement to Fund Phyto Pain Pharma Clinical Trials

    6 December 2016
    0 Views

    Ottawa, Ontario – (Marketwired – December 6, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE: TBP and OTC: GRPOF) is conducting a non-brokered private placement with Aphria Inc. (TSX-V: APH and USOTCQB: APHQF) of 5,000,000 units at a price of $0.20 per unit for aggregate gross proceeds of $1,000,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share of the Company at a price of $0.26 per share for a period of 3 years following the closing date. The warrants are subject to an accelerated expiry if the Company’s shares trade above $0.45 for thirty (30) consecutive trading days then the warrants will expire in 30 days if not exercised.

    Continue Reading
  • Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001

    23 November 2016
    0 Views

    Ottawa, Ontario – (Marketwired – November 23, 2016) – PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP and OTC: GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.

    Continue Reading
  • Tetra Bio-Pharma (GRPOF) Pioneers a New, Ancient Approach to Cannabinoid Delivery

    21 November 2016
    0 Views

    The vast majority of patients smoke medical marijuana rather than using edibles or pills. In fact, Canada only recently legalized non-smokable forms of medical marijuana under the ACMPR program. Although smoking may have a negative connotation due to tobacco’s reputation for causing lung cancer, smoked marijuana provides some very real benefits to patients relative to edibles, pills, and other modern delivery mechanisms.

    Continue Reading